Lilly joins the folate receptor arena
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
A Calquence win seven years in the making
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.
Bristol backs out of BET inhibition
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
Mythic goes back to basics
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
How hot are antibody-drug conjugates?
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Ascentage’s Venclexta challenge looks wildly optimistic
A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
